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.2013.04Abstract Background: As survival rates of pediatric acute lymphoblastic leukemia (ALL)
improve, attention is turning to side and late effects of therapy including glucose metabolism abnor-
malities.
Objective: To asses the presence of abnormal glucose metabolism in pediatric ALL survivors and
its possible relation to body mass index (BMI), waist to hip ratio and treatment related factors.
Subjects and methods: Retrospective study with a prospective follow-up of 12 ALL survivors who
had been off chemotherapy for >9 months was done. Fifteen healthy sex and age matched children
were involved as controls. Body mass index (BMI) waist to hip ratio (WHR), and Oral glucose tol-
erance test (OGTT) were performed with assessment of glycated hemoglobin (Hb A1C) and insulin
sensitivity indices.
Results: At study time the mean BMI, WHR, all components of the OGTT (except the 2 h post
load glucose), all indices of insulin sensitivity and the mean Hb A1C% were signiﬁcantly higher
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8 F.H. El-Rashedy et al.during therapy, one (8.3%) had pre-diabetes, seven (58.3%) had a risk level of Hb A1C but no one
had diabetes mellitus (DM) or insulin resistance (IR). At study time the two survivors with transient
hyperglycemia during therapy had a signiﬁcantly high WHR compared to the remainders. WHR of
the survivors at study time correlated signiﬁcantly with fasting plasma glucose and area of insulin
under the curve (AUC). The 2 h post-prandial plasma glucose correlated with the duration after
therapy completion.
Conclusions: WHR may play a better role than BMI in the prediction of insulin resistance in those
patients. Hb A1C may increase earlier than other indices of glucose tolerance.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association.1. Introduction
Survival after childhood acute lymphoblastic leukemia (ALL)
has improveddramatically during the last decades, which empha-
sizes the importance of long-term treatment complications.1
ALL survivors are known to experience a variety of late ef-
fects that could impact on their future health, including abnor-
malities of growth and endocrine function,2 cardiac
dysfunction,3 and subsequent malignant neoplasms.4
Obesity is a well-recognized treatment-related complica-
tion, particularly following childhood ALL.5,6
Excessive weight gain during ALL treatment is usually re-
lated to steroid effects and CNS treatment on appetite regula-
tion, as well as less energy expenditure. Nevertheless, these
factors do not fully explain overweight in this group of
patients.7
Body mass index (BMI) is a number calculated from a
child’s weight and height. BMI is a reliable indicator of body
fatness for most children and teens.8
Besides obesity ALL survivors are recognized to present
clinical features of metabolic syndrome,9 and therefore in-
creased risk factors for visceral obesity10 insulin resistance
(IR) and glucose intolerance.11
IR is deﬁned as an impaired ability of plasma insulin at
usual concentrations to adequately promote peripheral glucose
disposal, suppress hepatic glucose, and inhibit very low density
lipoprotein (VLDL) output, but it can be inferred on strong
clinical evidence and conﬁrmed by insulin and glucose
measurements.12
It is associated with numerous physical health ﬁndings that
have serious consequences such as obesity, hyperlipidemia,
hypertension, cardiovascular disease, and type 2 diabetes.
The clustering of these diseases is termed insulin resistance
syndrome.13
Waist to hip ratio, is an indicator of abdominal obesity and
is a predictor of glucose metabolism abnormalities in children
and adults.12
The objective of this study was to assess the presence of
abnormal glucose metabolism in pediatric (ALL) survivors
and its possible relation to body mass index (BMI), waist to
hip ratio and treatment related factors.
2. Subjects and methods
2.1. Subjects
The present study recruited ALL survivors who were diag-
nosed, treated and received their follow up care in Pediatricdepartment, Menouﬁya University Hospital, Hematology
and Oncology unit on cancer study group (CCG) protocol dur-
ing the period 2000–2008. This treatment protocol did not in-
volve cranial radiotherapy. The eligible population consisted
of children (ageP1 year and 618 years) who had not received
chemotherapy in at least 9 months. Patients were ineligible if
they had relapsed, had pre-existing type 1 diabetes (before
diagnosis of ALL) leaving 15 potentially eligible survivors.
The rationale for the exclusions was to leave a sample to which
abnormalities in weight status or body composition might be
attributable to ALL or its treatment. The eligible survivors
were invited to participate but only 12 (80%) had agreed.
The included ALL survivors (seven males and ﬁve females)
had age ranging between 3 and 12 years (7 ± 3) at the time
of diagnosis. At study time, their ages ranged between 7 and
18 years (11.5 ± 3.4). Five of them (41.7%) had family history
of type 1 diabetes mellitus.
Fifteen healthy children with matched age (11.6 ± 3.74),
sex (nine males and six females) and family history of type 1
diabetes (four out of 15; 26.7%) were enrolled as a control
group.
The Ethics Committee approved the study. Study partici-
pants’ caregivers provided informed consent to their children’s
participation.
2.2. Methods
All participations were subjected to the following:
(I) Full history taking including family history of diabetes
mellitus. Data regarding the subject’s ALL treatment were col-
lected from the medical record on a separate occasion. Infor-
mation gathered included date of diagnosis, age, height and
weight at diagnosis, ﬁrst recorded serum glucose level, three
highest serum glucose levels recorded during treatment, details
of chemotherapy including type of steroid used, total cumula-
tive doses of asparaginase, dexamethasone, and/or prednisone,
and date of completion of therapy. All survivors had received
dexamethazone. The total asparaginase dose was expressed as
the number of courses of asparaginase. One course of L-aspar-
aginase refers to either the nine injections of 6000 units/m2
used in the induction phase of chemotherapy or the six injec-
tions of 6000 units/m2 used in other chemotherapy phases.
Subjects were deﬁned as having transient hyperglycemia if they
had greater than two random glucose levels greater than
200 mg/dl.14
(II) Thorough clinical examination.
(III) Anthropometric measurements including:
Glucose metabolism abnormalities among pediatric acute lymphoblastic leukemia survivors 9Height and weight were measured to 0.1 cm and 0.1 kg,
respectively, using a Scale-Tronix stand on scale 5002 while pa-
tients removed shoes and outdoor clothes.
Body mass index was calculated as weight in kilograms di-
vided by height in meters squared (BMI, kg/m2) both at diag-
nosis and at study time for survivors.
The BMI was expressed as an age and sex speciﬁc z-score or
centile. Egyptian BMI reference data are available15 in the
form of centile charts for boys and girls and so these were used
in the present study. Various international BMI for age refer-
ence data are available, the most widely used are probably
those provided by the US Centers for Disease control and pre-
vention (CDC).16 Both of these were used in the present study.
BMI z-scores were calculated from WHO 2007 reference data
using WHO Anthro version 3.2.2, January 2011 software.17
BMI z-scores were calculated relative to US CDC reference
data. When using Egyptian and US CDC BMI for age refer-
ence data obesity was deﬁned conventionally, asP95th centile,
overweight as 85th to 94th centile, and underweight as <5th
percentile.16 According to WHO classiﬁcation of BMI
2007,17 a person with BMI z-score > 2SD is considered obese,
this with >1SD is considered overweight and if <2SD is con-
sidered thin.
Waist and hip circumferences (cm) were measured while the
subjects were wearing light clothing. Waist circumference was
measured at the minimum circumference between the iliac crest
and the rib cage. Hip circumference was measured at the max-
imum protuberance of the buttocks, and the waist/hip ratio
(WHR) was calculated.18
(IV) Laboratory investigations including:
Oral glucose-tolerance test (OGTT):
At 8–9 AM, after a 10-h to 12-h overnight fast, baseline
blood samples were obtained for measurements of glycosylated
hemoglobin (Hb A1c), fasting plasma glucose and fasting insu-
lin. Thereafter, glucose in a dose of 1.75 g/kg of body weight
(up to a maximum of 75 g) was given orally, and blood sam-
ples were obtained every 30 min for 120 min for measurements
of plasma glucose and insulin.
Blood samples were transferred into sodium ﬂuoride tubes
and then centrifuged. Blood glucose level was plotted against
time to draw glucose tolerance curve.
Blood glucose was determined by enzymatic colorimetric
test using Spin react kit, SPAIN.19
Impaired glucose tolerance (IGT) was deﬁned, according to
the American Diabetes Association guideline, 201220 as a fast-
ing plasma glucose level of 101–125 mg/dl and a 2-h plasma
glucose level of 140–199 mg/dl; diabetes was deﬁned as a fast-
ing plasma glucose level of 126 mg/dl or higher or a 2-h plasma
glucose level of more than 200 mg/dl or higher.
Fasting and 2-h postprandial serum insulin levels (lU/mL)
were determined by enzyme linked immunosorbent assay
method, using DRG Insulin ELISA kit, Germany.21
IR is diagnosed when person has fasting insulin level
>15 lU/mL or if the peak insulin level >150 lU/mL.12
The results were used to calculate the insulin and glucose
area under the curve (AUC) and the homeostatic model assess-
ment of IR [(HOMA index) = fasting glucose (mg/dl) · fast-
ing insulin (lU/mL)/constant (405)].22 According to Valerioet al.23 a cut-off HOMA level of >2.5 in children and >4.0
in adolescents was used to identify an insulin-resistance status.
Glycated hemoglobin (Hb A1c) was determined by quanti-
tative colorimetric measurement as percent of total hemoglo-
bin using kits supplied by Teco diagnostics, USA.24
According to the American Diabetes Association guideline,
201220 normal level of Hb A1C is that <5.6%, if between
5.7% and 6.4% the person is of the category of an increased
risk for diabetes and diabetes is diagnosed if it is P6.5%.
2.3. Statistical analysis
Results were collected, tabulated, statistically analyzed by
IBM personal computer and Statistical Package for the Social
Sciences (SPSS) version 16. Differences between the groups
were evaluated by the non-parametric Mann–Whitney test.
Chi-square test (v2) was used to study the relation between
two qualitative variables. Spearman rank test for p-value of
60.05 was considered statistically signiﬁcant.253. Results
All of the involved survivors had received dexamethasone with
the mean cumulative dose of 869 ± 150 mg/m2. The mean per-
centage of L-asparginase courses taken was 90 ± 10%.
The subjects had been off therapy for a mean of
24.33 months (SD ± 18.18, range 9–60 months).
The mean BMI at the time of the diagnosis did not differ
than that of the control while, at study time the mean BMI
and WHR were signiﬁcantly higher compared to those of the
controls.
According to the WHO BMI z-score and CDC classiﬁca-
tion of BMI centiles, 16.6% of the studied survivors were over-
weight and obese at the time of diagnosis, that increased to be
25% at the study time percentages that were higher compared
to the controls (Table 1).
On individual level, all the included 15 healthy children had
normal OGT values and Hb A1C% with no one having IR.
While among the studied 12 ALL survivors two (16.6%)
developed transient hyperglycemia during therapy, one
(8.3%) had IGT = pre-diabetes (2 h post load glucose
>140), seven out of the 12 survivors (58.3%) had a risk level
of Hb A1C (between 5.7% and 6.4%) but no one had DM or
IR.
All components of the OGTT except the 2 h post load glu-
cose were signiﬁcantly higher in the ALL survivors compared
to those of the controls.
Also the means of all indices of insulin sensitivity (fasting,
2 h post load insulin, HOMA IR index and area of insulin un-
der the curve) together with the mean glycated Hb% of the
ALL survivors were signiﬁcantly higher compared to those
of the controls (Table 1).
The overweight and obese ALL survivors according to the
WHO BMI z-score classiﬁcation (either at the time of diagno-
sis or at study time), did not differ in WHR ratio or any of
insulin sensitivity indices compared to non-overweight survi-
vors at the corresponding times (Table 2).
At study time the two survivors with transient hyperglyce-
mia during therapy had a signiﬁcantly high WHR compared to
Table 1 Comparison between survivors and the control group regarding clinical and demographic data.
Survivors Controls Test value p-Value
Age at study (years) 11.5 ± 3.4 11.46 ± 3.74 0.099 0.92
Age at diagnosis (years) 7 ± 3
Sex (male/female) 7/5 (58.3/41.7%) 9/6 (60/40%) 0.008 0.93
Family history of DM (yes/no) 5/7 (41.7/58.3%) 4/11 (26.7/73.3%) 0.675 0.411
BMI at diagnosis 16.12 ± 2.07 1.860 0.06
BMI at the time of the study 17.86 ± 2.96 14.59 ± 0.46 3.202 0.001a
BMI z-score for age at diagnosis
Normal 10 (83.3%) 15 (100%)
>1SD (overweight) 1 (8.3%)
>2SD (obese) 1 (8.3%) 0.1
Non overweight 10 (83.4%)
Overweight 2 (16.6%) 2.700
BMI z-score for age at study time
Normal 8 (66.7%)
>1SD (overweight) 3 (25.0%)
<2SD (thin) 1 (8.3%)
Non overweight 9 (75%) 4.21 0.04a
Overweight 3 (25%)
BMI centiles at diagnosis
<5 1 (8.3%) 0
5–85 9 (75.1) 15 (100%)
85–95 1 (8.3%) 0 0.1
>95 1 (8.3%) 0
Non overweight 10 (83.4%)
Overweight 2 (16.6%) 2.700





Non overweight 9 (75%) 4.21 0.04a
Overweight 3 (25%)
WHR at study time 0.92 ± 0.022 0.75 ± 0.06 4.40 0.000a
Random blood sugar (mg/dl) 128.17 ± 13.16 98.93 ± 8.87 4.29 0.000a
Fasting glucose in OGTT (mg/dl) 80.58 ± 9.85 71.40 ± 5.38 2.65 0.008 a
1/2 h glucose in OGTT (mg/dl) 125.58 ± 20.49 108.40 ± 5.38 2.21 0.027a
1 h glucose in OGTT (mg/dl) 103.84 ± 15.36 92.20 ± 9.77 2.22 0.026a
2 h glucose in OGTT (mg/dl) 85.25 ± 26.98 70.66 ± 15.35 1.35 0.177
Fasting insulin (lU/mL) 3.27 ± 2.32 1.59 ± 1.29 2.20 0.028a
2 h post-prandial Insulin (lU/mL) 7.58 ± 3.42 3.36 ± 1.24 3.08 0.002a
Homa IR 0.63 ± 0.44 0.28 ± 0.23 2.489 0.013a
AUC 34.98 ± 28.18 7.44 ± 6.09 3.230 0.001a
Glycated Hb% 5.74 ± 0.79 3.80 ± 0.26 4.427 0.000a
Cumulative dose of steroid (mg/m2) 869 ± 150
Percentage of asparginase courses (%) 90 ± 10
Type of steroid during induction Dexamethasone
Duration after therapy range (months) 9–60
24.33 ± 18.18
a Signiﬁcant.
10 F.H. El-Rashedy et al.the remainders without signiﬁcant differences in any of the
insulin sensitivity indices (Table 3).
There were non signiﬁcant correlations between any of the
insulin sensitivity indices at the time of the study and patients
data (age at study and at diagnosis, mean BMI at diagnosis
and at study time, duration after completion of chemotherapy,cumulative dose of steroid (mg/m2), the % of L-asparginase
courses) (Table 4).
WHR of the survivors at study time correlated signiﬁcantly
with fasting plasma glucose and area of insulin under the curve
(AUC) (Figs. 1 and 2).While the 2 hpost-prandial plasmaglucose
correlated with the duration after therapy completion (Fig. 3).








HOMA index Insulin AUC
Overweight at diagnosis Non overweight (n= 10) 0.92 ± 0.02 79.9 ± 9.87 3.5 ± 2.5 6.99 ± 3.30 0.69 ± 0.47 33.95 ± 30.10
Overweight and obese (n= 2) 0.91 ± 0.02 84.0 ± 12.73 1.9 ± 0.6 10.50 ± 3.11 0.39 ± 0.06 40.12 ± 22.80
Test value 0.439 0.538 0.859 1.50 0.859 0.645
p-Value 0.66 0.591 0.390 0.132 0.390 0.519
Overweight at study Non overweight (n= 9) 0.92 ± 0.02 82.11 ± 8.19 3.05 ± 2.45 6.90 ± 3.53 0.62 ± 0.49 30.61 ± 29.15
Overweight (n= 3) 0.93 ± 0.035 76.0 ± 14.93 3.93 ± 2.15 9.6 ± 2.51 0.68 ± 0.31 48.07 ± 25.03
Test value 0.44 1.02 0.86 1.51 0.86 0.64
p-Value 0.66 0.32 0.39 0.13 0.39 0.51
Table 3 Comparison between hyperglycemic and non-hyperglycemic patients during therapy regarding WHR and insulin sensitivity







HOMA index Insulin AUC
Hyperglycemia during therapy No (n= 10) 0.915 ± 0.15 80.80 ± 9.91 3.0 ± 2.4 7.67 ± 3.74 0.59 ± 0.47 34.90 ± 30.74
Yes (n= 2) 0.95 ± 0.02 79.50 ± 13.43 4.65 ± 1.3 7.10 ± 1.27 0.89 ± 0.11 35.37 ± 15.37
Test value 2.19 0.43 1.5 0.000 1.72 0.43
p-Value 0.028a 0.67 0.13 1.00 0.09 0.67
a Signiﬁcant.
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The presence of glucose metabolism abnormalities among
pediatric ALL survivors has been documented in different
studies.26–28
Mohn et al.27 reported an impaired insulin response in pa-
tients who had been off therapy for 1 year, but over time, this
impairment resolved.29 However, some studies suggest that
some childhood ALL survivors, depending on therapy, may
have a persistent risk of insulin resistance in their young adult
years.11,28
Compared to the controls, the mean values of all compo-
nents of the OGTT except the 2 h post load glucose, all indicesFig. 1 Correlation between WHR and fasting insulin.
Fig. 2 Correlation between WHR and area of insulin under the
curve.of insulin sensitivity (fasting, 2 h post load insulin, HOMA IR
index and area of insulin under the curve) together with the
mean % of glycated Hb were signiﬁcantly higher in the in-
volved ALL survivors.
While on an individual level, among the studied 12 ALL
survivors, only one (8.3%) had been found to have impaired
glucose tolerance in the form of high 2 h post load glucose
(148 mg/dl = pre-diabetic level) with high Insulin AUC
(47.61) and with Hb A1C level of 6.4% (category of increased
risk for diabetes) but other wise he did not have any symptoms
of DM and his other laboratory data are within normal range.
This survivor was 13 years at the study time, and was not over-
weight either according to BMI centiles or BMI z-score. His
cumulative dose of steroids was the highest among the 12 sur-
vivors (1000 mg/m2) and completed 80% of his asparaginase
Fig. 3 Correlation between duration after therapy completion
and 2 h post load glucose.
12 F.H. El-Rashedy et al.courses without any documented transient hyperglycemia dur-
ing therapy. This adolescent survivor had completed his ther-
apy since 60 months (the longest duration among the studied
survivors).
IR is not documented in any of the ALL survivors or the
controls.
Against these results, Lowas et al.30 documented IR in eight
out of the studied 27 ALL survivors (29.6%) and one subject
had pre-diabetes (with a fasting glucose level of 101 mg/dl,
but this subject’s 120-min glucose level was less than 140 mg/
dl). Also Surapolchai and co-workers31 had reported IGT in
10 out of 131 Thailand ALL survivors (7.6%) whereas 40
(30.5%) had IR. These two studies did not involve healthy
control group.
Recent studies suggest that ALL survivors have an in-
creased prevalence of obesity.5,6,32,33
We have selected BMI as a surrogate measure of body fat-
ness. BMI is the standard index used in clinical studies of obes-
ity in adults and has been shown to correlate with other indices
of body fat in children and adolescents.34
In the present study, two out of the 12 survivors (16.8%)
were overweight or at risk at the time of diagnosis by applying
the international approaches based on BMI (centiles and z-
score) that did not differ signiﬁcantly compared to the con-
trols. This percentage increased to be 25% (three out of 12)
at the study time (an average of 5 years after completion ofTable 4 Correlations between insulin sensitivity indices and clinica
Hb A1C Insulin AUC HOMA index 2 h post-pran
Sig. r Sig. r Sig. r Sig.
0.643 0.150 0965 0.014 0.877 0.050 0.960
0.163 0.43 0.645 0.148 0.785 0.088 0.537
0.590 0.173 0.863 0.056 0.372 0.284 0.854
0.768 0.095 0.240 0.368 0.121 0.473 0.279
0.363 0.288 0.047a 0.582 0.101 0.497 0.488
0.365 0.287 0.965 0.014 0.888 0.046 0.650
0.412 0.261 0.545 0.194 0.084 0.518 0.688
0.169 0.599 0.931 0.028 0.697 0.126 0.888
0.785 0.088 0.925 0.030 0.981 0.008 0.860
a Signiﬁcant.chemotherapy) and this differed signiﬁcantly with controls.
Also the mean BMI of the survivors at study time was signif-
icantly higher than that of the controls that was not true at the
time of diagnosis.
Based on U.S. Centers for Disease Control and Prevention
(CDC) deﬁnition growth charts, Salazar-Martinez et al.35 re-
ported that the prevalence of overweight and obesity was
12.1% and 6.2%, respectively, among the healthy Egyptian
adolescents. Back to the results of this work, it could be ob-
served that, overweight and obesity were more prevalent in
ALL survivors compared to general Egyptian population. This
supports the role of chemotherapy in acquiring overweight in
ALL survivors.
The results of this study come in agreement with those of
Lowas et al.27 who documented overweight or at risk in seven
out of 27 studied group (25.9%) at the time of diagnosis that
increased to 15 (55.6%) at study time after an average of
2.8 years off therapy. The higher percentage of overweight in
the latter study can be explained by the involvement of cranial
or cranio–spinal radiotherapy in three out of the 27 survivors
(11.1%) as children with ALL given cranial radio-therapy
(CRT) developed increases in their BMI-standard deviation
score (z-score) early on and during treatment and remain at
a signiﬁcant risk for becoming overweight as young adults.36
One previous study also based on Korean children with
ALL found a trend toward continued increase in BMI even
after treatment completion.37
In Saudi study performed on 56 adolescent ALL survivors,
with a mean age of 13.4 years a mean of 9.1 years post-diagno-
sis who did not receive CRT, the prevalence of BMI for age de-
ﬁned overweight and obesity (combined 28.5%) were actually
lower than in the general population in Saudi Arabia. The
authors suggested that overweight and obesity observed are
probably not an ALL speciﬁc problem.38
It is known that adiposity, particularly abdominal adipos-
ity, is associated with increased insulin resistance.12,39
Lowas et al.30 reported that the elevated BMI for age at the
time of study was a strong, consistent predictor of insulin resis-
tance as it correlated signiﬁcantly with several measures of
insulin resistance. Waist/hip ratio and BMI at ALL diagnosis
also correlated with insulin resistance. Variations in
ALL therapy, total doses of steroids and presence of tran-
sient hyperglycemia did not appear to increase risk of glucose
intolerance or insulin resistance.l assessment data at the time of the study.
dial insulin Fasting insulin Item
r Sig. r
0.016 0.991 0.004 Age at study
0.198 0.983 0.007 Age at diagnosis
0.060 0.359 0.291 BMI at diagnosis
0.340 0.158 0.434 BMI at study
0.222 0.044a 0.589 WHR
0.146 0.820 0.074 Duration after completion of
chemotherapy (months)
0.130 0.139 0.453 Hyperglycemia during therapy
0.046 0.681 0.133 Cumulative dose of steroid (mg/m2)
0.057 0.768 0.095 Courses of L-asparginase
Glucose metabolism abnormalities among pediatric acute lymphoblastic leukemia survivors 13In this study, overweight and obese ALL survivors (either
at time of diagnosis or at study time), did not differ in any
of insulin sensitivity indices compared to non-overweight sur-
vivors at the corresponding times. Further more BMI (either at
time of diagnosis or at study time) did not correlate to any of
insulin sensitivity indices.
Warner et al.40 found that the BMI for age provided a poor
indicator of excess adiposity in patients with childhood cancer
and other chronic diseases.
Studying WHR as another indicator of central obesity, the
mean WHR of the studied survivors was signiﬁcantly higher
compared to that of the controls. It was the only variable that
correlated to some of insulin sensitivity indices (fasting insulin
and insulin AUC) while other variables including cumulative
steroid dose and courses of L-asparginase percentage did not.
Several studies have noted an increased incidence of tran-
sient hyperglycemia during remission induction treatment for
childhood ALL.26,30,41,42 Some have suggested that there
may be a lasting hyperglycemic effect on patients with or pre-
disposed to diabetes.43
Among the studied 12 ALL survivors, two (16.6%) devel-
oped transient hyperglycemia during therapy.
At the study time these survivors had a signiﬁcantly high
WHR compared to the remainders without signiﬁcant differ-
ences in any of the insulin sensitivity indices. This strengthens
the relation of WHR to insulin sensitivity indices in ALL
survivors.
Presence of hyperglycemia during therapy did not have any
relation to insulin sensitivity indices at study time. This comes
in accordance with previous studies which found no relation-
ship between transient hyperglycemia during treatment and
glucose intolerance in the ﬁrst several years after treatment
completion.30,44
In this work duration after therapy completion had corre-
lated to 2 h post load glucose and this may denote that long
term follow up for these survivors is needed to demonstrate
the possible disturbance in glucose metabolism that may occur.
The present study was limited by small sample size, 12 sub-
jects were studied instead of the 15 originally planned. One
reason for this was the difﬁculty in subject recruitment due
to lack of interest of the parents. Another limitation was the
short time between end of the therapy and the present study.
Additional limitations include the variation in age and time
off therapy of the subjects. These, too, were related to the few
adolescents who participated.
6. Conclusions
It can be concluded that, although the mean values of OGT
test and IS indices were higher in ALL survivors compared
to healthy controls, none of the values were high enough to
indicate a disease process such as insulin resistance on an indi-
vidual level.
There was no role of BMI in the prediction of insulin resis-
tance as a late effect of chemotherapy in pediatric ALL survi-
vors, but WHR may play a better role in the prediction of
insulin resistance in those patients.
Hb A1C may increase earlier than other indices of glucose
tolerance.
The potential for late-onset of metabolic syndrome still ex-
ists, demanding a long-term longitudinal research and longerfollow-up to gain better understanding of predisposing factors
of glucose metabolism alteration in ALL survivors. The late ef-
fects of chemotherapy on glucose metabolism still deserve fur-
ther research on a study of a larger population sample.
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